Assertio reports second quarter 2025 financial results

Second quarter total net product sales of $28.8 million, cash and investments increase to $98.2 million narrows guidance on continued progress implementing long-term business strategy lake forest, ill., aug. 11, 2025 (globe newswire) -- assertio holdings, inc. (“assertio” or the “company”) (nasdaq: asrt), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the second quarter ended june 30, 2025.
ASRT Ratings Summary
ASRT Quant Ranking